Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + POFI in Advanced Gastric Cancer
NCT05319639Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), sponsored by Fujian Medical University Cancer Hospital. Started Feb 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05319639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319639.